Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Non-Current Debt (2016 - 2025)

Integra Lifesciences Holdings' Non-Current Debt history spans 17 years, with the latest figure at $1.7 billion for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 58.98% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, up 58.98%, while the annual FY2025 figure was $1.7 billion, 58.98% up from the prior year.
  • Non-Current Debt for Q4 2025 was $1.7 billion at Integra Lifesciences Holdings, up from $1.7 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $1.7 billion in Q4 2025 and bottomed at $733.1 million in Q4 2022.
  • The 5-year median for Non-Current Debt is $837.8 million (2023), against an average of $1.0 billion.
  • The largest annual shift saw Non-Current Debt dropped 18.28% in 2021 before it skyrocketed 58.98% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $824.3 million in 2021, then dropped by 11.05% to $733.1 million in 2022, then grew by 12.61% to $825.6 million in 2023, then skyrocketed by 31.78% to $1.1 billion in 2024, then skyrocketed by 58.98% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Non-Current Debt are $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.1 billion (Q2 2025).